This trial will study how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides.
- Mycosis Fungoides
- Sezary Syndrome
- Mycosis Fungoides and Sezary Syndrome
1 Primary · 6 Secondary · Reporting Duration: Time from registration to CR, CR90 or PR, assessed up to 1 year
Side Effects for
1 Treatment Group
1 of 1
10 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 18 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are some of the conditions that Pembrolizumab has been helpful in treating?
"Pembrolizumab is a medication used to treat various conditions, including malignant neoplasms, unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy." - Anonymous Online Contributor
Could you please list other instances in which Pembrolizumab has been studied?
"There are currently 1000 ongoing clinical trials involving pembrolizumab, with 122 of them being in Phase 3. Pembrolizumab studies are largely based out of Houston, Texas; however, there are 36030 medical sites running trials for this medication." - Anonymous Online Contributor
How many people are receiving care through this clinical trial?
"That is accurate. The clinicaltrials.gov website currently hosts information indicating that this study is still looking for participants. December 20th, 2018 was the first time this trial was posted and it has seen one update on March 22nd, 2022. This research project is only recruiting 28 individuals from a single location." - Anonymous Online Contributor
Has Pembrolizumab been cleared by the FDA?
"Pembrolizumab's safety is rated as a 2 since there is only limited data supporting its efficacy and safety." - Anonymous Online Contributor
Are researchers still looking for participants in this clinical trial?
"That is correct. Based on the information available from clinicaltrials.gov, this study appears to be open and recruiting patients. The listing for this trial was first posted on December 20th, 2018 with the most recent update occurring March 22nd, 2022. So far, 28 people have been enrolled at a single centre." - Anonymous Online Contributor